Selected research
Industry Research
Afatinib Dimaleate Industry Research Report 2026
Market perspective
The global Afatinib Dimaleate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Afatinib Dimaleate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Afatinib Dimaleate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Afatinib Dimaleate include Boehringer-Ingelheim, Beacon Pharmaceuticals, Hansoh Pharmaceuticak, Kelun－Kazpharm, Merck, Qilu Pharmaceutical, Qingfeng Medicine Group, CSPC Pharmaceutical and Yangtze River Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Afatinib Dimaleate market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Afatinib Dimaleate Market by Company
Boehringer-Ingelheim
Beacon Pharmaceuticals
Hansoh Pharmaceuticak
Kelun－Kazpharm
Merck
Qilu Pharmaceutical
Qingfeng Medicine Group
CSPC Pharmaceutical
Yangtze River Pharm
Chia Tai-Tianqing
Afatinib Dimaleate Segment by Type
20 mg
30 mg
40 mg
Afatinib Dimaleate Segment by Application
Hospital
Clinic
Afatinib Dimaleate Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Afatinib Dimaleate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Afatinib Dimaleate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Afatinib Dimaleate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Afatinib Dimaleate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Afatinib Dimaleate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Afatinib Dimaleate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 20 mg
- 30 mg
- 40 mg
Applications
- Hospital
- Clinic
Companies covered
- Boehringer-Ingelheim
- Beacon Pharmaceuticals
- Hansoh Pharmaceuticak
- Kelun－Kazpharm
- Merck
- Qilu Pharmaceutical
- Qingfeng Medicine Group
- CSPC Pharmaceutical
- Yangtze River Pharm
- Chia Tai-Tianqing
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Afatinib Dimaleate Market Size (2021-2032)
- 2.2.2 Global Afatinib Dimaleate Sales (2021-2032)
- 2.2.3 Global Afatinib Dimaleate Market Average Price (2021-2032)
- 2.3 Afatinib Dimaleate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 20 mg
- 2.3.3 30 mg
- 2.3.4 40 mg
- 2.4 Afatinib Dimaleate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Afatinib Dimaleate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Afatinib Dimaleate Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Afatinib Dimaleate Revenue of Manufacturers (2021-2026)
- 3.4 Global Afatinib Dimaleate Average Price by Manufacturers (2021-2026)
- 3.5 Global Afatinib Dimaleate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Afatinib Dimaleate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Afatinib Dimaleate, Product Type & Application
- 3.8 Global Manufacturers of Afatinib Dimaleate, Established Date
- 3.9 Global Afatinib Dimaleate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boehringer-Ingelheim
- 4.1.1 Boehringer-Ingelheim Company Information
- 4.1.2 Boehringer-Ingelheim Business Overview
- 4.1.3 Boehringer-Ingelheim Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boehringer-Ingelheim Afatinib Dimaleate Product Portfolio
- 4.1.5 Boehringer-Ingelheim Recent Developments
- 4.2 Beacon Pharmaceuticals
- 4.2.1 Beacon Pharmaceuticals Company Information
- 4.2.2 Beacon Pharmaceuticals Business Overview
- 4.2.3 Beacon Pharmaceuticals Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Beacon Pharmaceuticals Afatinib Dimaleate Product Portfolio
- 4.2.5 Beacon Pharmaceuticals Recent Developments
- 4.3 Hansoh Pharmaceuticak
- 4.3.1 Hansoh Pharmaceuticak Company Information
- 4.3.2 Hansoh Pharmaceuticak Business Overview
- 4.3.3 Hansoh Pharmaceuticak Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hansoh Pharmaceuticak Afatinib Dimaleate Product Portfolio
- 4.3.5 Hansoh Pharmaceuticak Recent Developments
- 4.4 Kelun－Kazpharm
- 4.4.1 Kelun－Kazpharm Company Information
- 4.4.2 Kelun－Kazpharm Business Overview
- 4.4.3 Kelun－Kazpharm Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kelun－Kazpharm Afatinib Dimaleate Product Portfolio
- 4.4.5 Kelun－Kazpharm Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Afatinib Dimaleate Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Qilu Pharmaceutical
- 4.6.1 Qilu Pharmaceutical Company Information
- 4.6.2 Qilu Pharmaceutical Business Overview
- 4.6.3 Qilu Pharmaceutical Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Qilu Pharmaceutical Afatinib Dimaleate Product Portfolio
- 4.6.5 Qilu Pharmaceutical Recent Developments
- 4.7 Qingfeng Medicine Group
- 4.7.1 Qingfeng Medicine Group Company Information
- 4.7.2 Qingfeng Medicine Group Business Overview
- 4.7.3 Qingfeng Medicine Group Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Qingfeng Medicine Group Afatinib Dimaleate Product Portfolio
- 4.7.5 Qingfeng Medicine Group Recent Developments
- 4.8 CSPC Pharmaceutical
- 4.8.1 CSPC Pharmaceutical Company Information
- 4.8.2 CSPC Pharmaceutical Business Overview
- 4.8.3 CSPC Pharmaceutical Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CSPC Pharmaceutical Afatinib Dimaleate Product Portfolio
- 4.8.5 CSPC Pharmaceutical Recent Developments
- 4.9 Yangtze River Pharm
- 4.9.1 Yangtze River Pharm Company Information
- 4.9.2 Yangtze River Pharm Business Overview
- 4.9.3 Yangtze River Pharm Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Yangtze River Pharm Afatinib Dimaleate Product Portfolio
- 4.9.5 Yangtze River Pharm Recent Developments
- 4.10 Chia Tai-Tianqing
- 4.10.1 Chia Tai-Tianqing Company Information
- 4.10.2 Chia Tai-Tianqing Business Overview
- 4.10.3 Chia Tai-Tianqing Afatinib Dimaleate Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Chia Tai-Tianqing Afatinib Dimaleate Product Portfolio
- 4.10.5 Chia Tai-Tianqing Recent Developments
5 Global Afatinib Dimaleate Market Scenario by Region
- 5.1 Global Afatinib Dimaleate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Afatinib Dimaleate Sales by Region: 2021-2032
- 5.2.1 Global Afatinib Dimaleate Sales by Region: 2021-2026
- 5.2.2 Global Afatinib Dimaleate Sales by Region: 2027-2032
- 5.3 Global Afatinib Dimaleate Revenue by Region: 2021-2032
- 5.3.1 Global Afatinib Dimaleate Revenue by Region: 2021-2026
- 5.3.2 Global Afatinib Dimaleate Revenue by Region: 2027-2032
- 5.4 North America Afatinib Dimaleate Market Facts & Figures by Country
- 5.4.1 North America Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Afatinib Dimaleate Sales by Country (2021-2032)
- 5.4.3 North America Afatinib Dimaleate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Afatinib Dimaleate Market Facts & Figures by Country
- 5.5.1 Europe Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Afatinib Dimaleate Sales by Country (2021-2032)
- 5.5.3 Europe Afatinib Dimaleate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Afatinib Dimaleate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Afatinib Dimaleate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Afatinib Dimaleate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Afatinib Dimaleate Market Facts & Figures by Country
- 5.7.1 South America Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Afatinib Dimaleate Sales by Country (2021-2032)
- 5.7.3 South America Afatinib Dimaleate Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Afatinib Dimaleate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Afatinib Dimaleate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Afatinib Dimaleate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Afatinib Dimaleate Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Afatinib Dimaleate Sales by Type (2021-2032)
- 6.1.1 Global Afatinib Dimaleate Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Afatinib Dimaleate Sales Market Share by Type (2021-2032)
- 6.2 Global Afatinib Dimaleate Revenue by Type (2021-2032)
- 6.2.1 Global Afatinib Dimaleate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Afatinib Dimaleate Revenue Market Share by Type (2021-2032)
- 6.3 Global Afatinib Dimaleate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Afatinib Dimaleate Sales by Application (2021-2032)
- 7.1.1 Global Afatinib Dimaleate Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Afatinib Dimaleate Sales Market Share by Application (2021-2032)
- 7.2 Global Afatinib Dimaleate Revenue by Application (2021-2032)
- 7.2.1 Global Afatinib Dimaleate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Afatinib Dimaleate Revenue Market Share by Application (2021-2032)
- 7.3 Global Afatinib Dimaleate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Afatinib Dimaleate Value Chain Analysis
- 8.1.1 Afatinib Dimaleate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Afatinib Dimaleate Production Mode & Process
- 8.2 Afatinib Dimaleate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Afatinib Dimaleate Distributors
- 8.2.3 Afatinib Dimaleate Customers
9 Global Afatinib Dimaleate Analyzing Market Dynamics
- 9.1 Afatinib Dimaleate Industry Trends
- 9.2 Afatinib Dimaleate Industry Drivers
- 9.3 Afatinib Dimaleate Industry Opportunities and Challenges
- 9.4 Afatinib Dimaleate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst